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The expression of c-myc proto-oncogene in spleen lymphocytes has been studied in lupus-prone mice (~RL/~~~r~~r), an animal model for the 
human autoimmune disease systemic lupus erythematosus, during the growing process, in comparison to control mice (~RL]~p-+/~). By 
Northern blot assay and nuclear un on transcription assay, we demonstrated the enhancement of c-myc proto-oncogene xpression in spleen lym- 
phocytes from lupus-prone mice in comparison to control mice and the level of expression of c-myc proto-oncogene increased uring the growing 
process and deterioration of lupus symptoms, such as production of autoantibodies and lymphoproliferation, in this study. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Systemic autoimmune disorders, such as systemic 
lupus erythematosus, are characterized by immunologi- 
cal dysfunction and connective tissue inflammation, 
William et al. [l] claimed that most autoimmune dis- 
orders could be considered benign proliferate disorders. 
Most of the fundamental causes of autoimmune dis- 
orders remain obscure. Proto-oncogenes, including c- 
m~c, are expressed in normal lymphocytes after stimu- 
lation with appropriate mitogens [2,3], and may play 
key roles in growth and differentiation. &B&9@- 
lprllpr mice, an animal model of human systemic lupus 
erythematosus, develop age-dependent progressive 
lupus symptoms, such as production of high titer auto- 
antibodies and accumulation of abnormal subset of 
lymphocytes [4]. 
In the present study, we examined the expression of 
c-myc proto-oncogene in spleen lymphocytes from 
lupus-prone mice (MRL/Mp-IprApr) during the grow- 
ing process in comparison to control mice 
(MRLfMp-+ /+). We also tried to examine the rela- 
tionships between the elevated level of c-myc transcrip- 
tion and deterioration of autoimmune symptoms. The 
results indicate a good correlation between these pa- 
rameters and their possible significance in the patho- 
physiology of lupus is discussed. 
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2.1. Animal 
MRL/Mp--lpr/ipr (MRL/lpr) and MRL/Mp- + / + (MRL/ f ) mice 
were obtained from Jackson Laboratory (Bar Harbor, ME) and 
maintained in our laboratory. We carefully checked for lupus symp- 
toms, such as production of autoantibodies, proteinuria due to renal 
disorder and lymphoadenopathy during the growing process in both 
strains [4]. 
2.2. Preparation of spleen lymphocytes 
Spleen l~phoc~es from lupus-prone mice (MRL/~pr) and control 
mice (MRL/+) were isolated by gentle separation on a wire mesh. 
The erythrocytes were removed by Ficoll-Paque, pH 7.2 (Pharmacia 
Fine Chemicals, NJ). The cell population was over 97% viable 
(Trypan blue exclusion). 
2.3. Preparation of RNA and Northern blot assay 
The isolation of polyadenylated RNA from spleen lymphocytes was 
done as described by Swab et al. [5]. RNA was quantitated spectro- 
photometrically at 260 nm and applied on 0.8% formaldehyde- 
agarose gels. Samples were transferred to a nylon membrane (Pall, 
NY), and baked under vacuum at 80°C for 2 h. Filters were hybridiz- 
ed overnight at 42’C with 32P-labelled probes for c-myc (Oncor Inc., 
CA) or actin (Wake Pure Chemical industries, Ltd, Japan). After 
washing in 1 x SSC (1.50 mM NaCI, 15 mM sodium citrate), 0.1% 
SDS at 6O”C, filters wre exposed to Kodak AR X-Omat films at 
- 70°C. 
2.4. Nuclear run on transcription assay 
Nuclei were prepared from the cells by lysing the cells in the solu- 
tion which contained 10 mM Tris (pH 7.5), 2 mM MgClr, 3 mM 
CaC12, 5 mM DTT and 0.02% of NP40, with subsequent centrifuga- 
tion through 2 M sucrose solution. Three million nuclei were sus- 
pended into 100~1 of 50% glycerol solution with 50 mM Tris (pH 
7.5), 5 mM MgCfz and 0.1 mM EDTA. The suspension of nuclei was 
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immediately mixed with an equal volume of buffer containing 0.2 M 
KCI, 5 mM MgClr, 5 mM DTT, 1 mM of ATP, CTP, GTP, and 200 
units of RNasin (ribonuclease inhibitor, 500 units, Amersham Inter- 
national plc, England). The preparation was then incubated at 28°C 
for 20 min after addition with SO&i of “P-radiolabelled UTP 
(3000 mCi/ml, Amersham Inc.). To the preparation were added SDS 
and EDTA solution to a final concentration of 1% and 5 mM respec- 
tively, followed by treatment with proteinase K (1 mg/ml) at 42°C for 
30 min. RNA was extracted with phenol and chloroform from the 
preparation and precipitated with ethanol. The pellet was resus- 
pended into 3 ml of hybridization buffer which contained 50% of for- 
mamide, 0.75 M NaCl, 0.5% of SDS, 2 mM of EDTA, 50 mM of 
Hepes (pH 7.0), one tenth dilution of Denhardt’s solution and 
denatured salmon sperm DNA (500 pg/ml) [6]. Finally, the prepara- 
tion was applied to the nitrocellulose filter onto which the c-myc 
probe (Oncor Inc. USA) or ,&actin probe (Wako Pure Chemical In- 
dustries, Ltd, Japan) had been dotted. After 24 h incubation, the 
filter was washed three times in 0.2 x SSC and 0.1% of SDS at 45”C, 
dried and exposed to X-ray film with intensifying screen at - 70°C. 
In some experiments, the hybridized dot was excised from the filter 
and directly counted with a p-counter [7]. 
3. RESULTS AND DISCUSSION 
As shown in fig.1, we found the enhancement of 
RNA expression of c-myc proto-oncogene in spleen 
lymphocytes from lupus-prone mice (MRLApr), as 
compared with healthy control mice (MRL/+). We 
detected no significant change of the RNA expression 
of actin gene between them (data not shown). We ex- 
amined the transcriptional level of c-myc proto- 
oncogene in spleen lymphocytes from lupus-prone and 
control mice by nuclear run on transcription assay. We 
show the representative data of nuclear run on assay in 
fig.2. As shown in fig.2, we first demonstrated that the 
enhancement of transcriptional level of c-myc proto- 
oncogene was important for the increased RNA for c- 
myc proto-oncogene in spleen lymphocytes from lupus- 
1 2 
Fig.1. Northern blot assay of c-myc proto-oncogene in spleen lym- 
phocytes from lupus-prone and control mice. 1, MRL/Mp-lpr/lpr (2 
months after birth); 2, MRL/Mp- + / + (2 months after birth). 
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Fig.2. Nuclear run on transcription assay of c-myc proto-oncogene 
and actin gene in spleen lymphocytes from lupus-prone and control 
mice. a, MRL/Mp-lprllpr (2 months after birth); b, MRL/Mp- + / + 
(2 months after birth). 
prone mice. We found no significant change of tran- 
scription of actin gene between lupus-prone and control 
mice. This amplification was unlikely to be due to gross 
genetic changes because when the DNA was digested 
with EcoRI and HindIII, and examined by Southern 
blot analysis with c-myc specific probe, no significant 
gene amplifications or gross translocations were ob- 
served (data not shown). The c-myc gene product has 
DNA-binding ability [8], localized in the nucleus [9] 
and is induced in proliferating or differentiating cells 
[lo]. Deregulation of c-myc transcription or transloca- 
tion may disrupt the normal cell control. Since the 
enhancement of transcription of c-myc proto-oncogene 
was detected in spleen lymphocytes from lupus-prone 
mice, there are many activational stages and/or steps of 
spleen lymphocytes from lupus-prone mice. 
We further examined the transcriptional change of c- 
myc proto-oncogene during the growing process in 
lupus-prone mice (fig.3). As shown in fig.3, we found 
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Fig.3. Expression of c-myc proto-oncogene in spleen lymphocytes 
from lupus-prone mice during the growing process. (A) Northern blot 
assay of c-myc RNA in spleen lymphocytes from MRL/Mp-lpr/lpr 
mice (1, 3, 5 and 7 months after birth). (B) Nuclear run on transcrip- 
tion assay of c-myc proto-oncogene xpression in spleen lymphocytes 
from MRL/Mp-/pr/lpr mice. a, 1 month after birth; b, 3 months after 
birth; c, 5 months after birth. 
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Table 1 
Correlation between c-myc expression in spleen lymphocytes and lupus symptoms in 
lupus-prone mice (MRL/Mp-lpr/lpr) 
Period after c-nryc Proteinuria Production of Lymphoadenopathy 
birth expression level autoantibodies level 
2 days + - - 
2 weeks + - 
2 months ++ + f + 
4 months +++ ++ ++ ++ 
6 months ++++ +++ +++ +++ 
Expression of c-myc was evaluated by Northern blot assay and nuclear run on assay. 
Levels of proteinuria, production of serum autoantibodies and lymphoadenopathy 
were evaluated by the usual laboratory and pathological examinations [4] 
the increase of expression of c-myc proto-oncogene in 
spleen lymphocytes from lupus-prone mice during the 
growing process. In table 1, which summarizes the re- 
sults, we also found a positive correlation between the 
transcriptional enhancement of c-pnyc proto-oncogene 
and deterioration of lupus symptoms, such as produc- 
tion of autoantibodies, proteinuria due to lupus-related 
renal disorders and lymphoadenopathy [4]., This result 
could suggest that the expression of c-myc proto- 
oncogene in spleen lymphocytes from lupus-prone mice 
could correlate with the disease activity of lupus. With 
respect o the pathophysiological meaning of lupus for 
the enhancement of c-myc gene transcription in spleen 
lymphocytes from lupus-prone mice, we found that the 
enhancement of the c-myc gene transcription preceded 
the exacerbation of lupus symptoms and changes in 
laboratory data such as the level of proteinuria and 
serum autoantibodies. Thus, we expect that the ex- 
amination of the mechanisms and factors which affect 
the enhanced transcription of c-myc proto-oncogene 
can give us the essential clue to the evaluation of the 
pathophysiology of lupus in lupus-prone mice. 
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